National Guard Health Affairs
14
0
0
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
14.3%
2 terminated/withdrawn out of 14 trials
50.0%
-36.5% vs industry average
14%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
Role: lead
Clinical Utilization of Newly Approved Oncology Medications
Role: lead
Risk Assessment Tool in Saudi Arabia
Role: lead
Quality of the End of Life Care
Role: lead
HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
Role: lead
Outcome of Pregnancy and Breast Cancer
Role: lead
Efficacy and Safety of the LovenoxTM (Enoxaparin) Versus HeparinTM Gynecologic Oncology Patients
Role: lead
Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer
Role: lead
Breast Cancer in Young Women: Is it Different?
Role: lead
Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer
Role: lead
Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients
Role: lead
Awareness and Attitude of Cancer Patients About Participation in Clinical Research (CR) in Saudi Arabia
Role: lead
Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
Role: lead
Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve Pancreatic Cancer
Role: lead
All 14 trials loaded